Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23977797 | 0.91 | MEN1 (0.33) | KDM4E | |
| SCHEMBL12120256 | 0.89 | KDM4E (0.33) | KDM4E | |
| SCHEMBL22137686 | 0.84 | HTT (0.33) | — | |
| SCHEMBL5002480 | 0.82 | MEN1 (0.41) | ALDH1A1SMN1; SMN2KDM4E | |
| SCHEMBL9705242 | 0.81 | ALDH1A1 (0.32) | ALDH1A1NPBWR1SMN1; SMN2MCHR1 | |
| SCHEMBL24245899 | 0.81 | MEN1 (0.33) | ALDH1A1 | |
| SCHEMBL22753504 | 0.81 | MEN1 (0.33) | ALDH1A1 | |
| SCHEMBL9700091 | 0.81 | ALDH1A1 (0.35) | ALDH1A1NPBWR1SMN1; SMN2MCHR1 | |
| SCHEMBL29339694 | 0.80 | BLM (0.46) | ALDH1A1NPBWR1SMN1; SMN2MCHR1KDM4E | |
| SCHEMBL25925304 | 0.80 | PIK3CD (0.43) | KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220389017-A1 | NOVEL PURINE DERIVATIVE, INTERMEDIATE AND APPLICATION THEREOF IN PREPARING ANTICANCER MEDICINE | SUZHOU RAYMON PHARMACEUTICALS COMPANY, LTD. (CN) | 2022-12-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220389017-A1 | NOVEL PURINE DERIVATIVE, INTERMEDIATE AND APPLICATION THEREOF IN PREPARING ANTICANCER MEDICINE | PNP, ENTPD5, NTPCR | ALDH1A1 999/4885NPBWR1 3852/4885SMN1; SMN2 3525/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.